What question did this study set out to answer?

Evaluate clinical outcomes of a non-radiation modified Baltimore reduced-intensity conditioning regimen combining fludarabine, cyclophosphamide, and busulfan in patients undergoing mismatched or haploidentical donor allogeneic stem cell transplantation.

September 17, 2026Annals of HematologyOpen Access

A Baltimore-modified non-TBI conditioning for allogeneic stem cell transplantation in elderly or unfit patients with haploidentical or mismatched donors

View Full Paper

Ask AI

Bookmark

Authors

VVVictoria Volpari CBClaude‐Eric Bulabois ATAnne Thiebaut‐Bertrand

Discussion

Member takes

Overview

Retrospective cohort study reveals acceptable survival without radiation conditioning in older transplant recipients, indicating a viable alternative when total body irradiation is inaccessible.

Key Points

Evaluate clinical outcomes of a non-radiation modified Baltimore reduced-intensity conditioning regimen combining fludarabine, cyclophosphamide, and busulfan in patients undergoing mismatched or haploidentical donor allogeneic stem cell transplantation.
Retrospective cohort study of 65 adult patients (median age 66 years; one-third with HCT-CI score ≥ 3) treated at Grenoble-Alpes University Hospital between March 2016 and April 2022.
Recipients underwent peripheral blood stem cell transplantation from haploidentical (43%) or mismatched unrelated (57%) donors using FE2B2 conditioning and post-transplant cyclophosphamide-based GVHD prophylaxis.
Primary endpoint was 2- and 5-year overall survival, with secondary endpoints evaluating engraftment, GVHD incidence, non-relapse mortality, and progression-free survival across a median follow-up of 61 months.
Neutrophil engraftment occurred in 100% of recipients and platelet engraftment in 97%, with cumulative grade II–IV acute GVHD of 45% (95% CI, 34–59%) and chronic GVHD of 20% (95% CI, 13–32%) at 2 and 5 years.
Non-relapse mortality was 22% (95% CI, 14–34%) at 2 years and 25% (95% CI, 17–39%) at 5 years, with four early fatal toxicities reported within the first 20 days.
Two- and 5-year overall survival rates were 48% (95% CI, 35–60%) and 37% (95% CI, 25–49%), while progression-free survival was 43% (95% CI, 31–55%) and 32% (95% CI, 21–44%), respectively.

Cite This Study

Volpari et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6635f706d05830e4d45 https://doi.org/10.1007/s00277-026-07260-1

View Full Paper

Ask AI

Bookmark

September 17, 2026Annals of HematologyOpen Access

A Baltimore-modified non-TBI conditioning for allogeneic stem cell transplantation in elderly or unfit patients with haploidentical or mismatched donors

View Full Paper

Ask AI

Bookmark

Authors

VVVictoria Volpari CBClaude‐Eric Bulabois ATAnne Thiebaut‐Bertrand

Discussion

Member takes

Overview

Retrospective cohort study reveals acceptable survival without radiation conditioning in older transplant recipients, indicating a viable alternative when total body irradiation is inaccessible.

Key Points

Evaluate clinical outcomes of a non-radiation modified Baltimore reduced-intensity conditioning regimen combining fludarabine, cyclophosphamide, and busulfan in patients undergoing mismatched or haploidentical donor allogeneic stem cell transplantation.
Retrospective cohort study of 65 adult patients (median age 66 years; one-third with HCT-CI score ≥ 3) treated at Grenoble-Alpes University Hospital between March 2016 and April 2022.
Recipients underwent peripheral blood stem cell transplantation from haploidentical (43%) or mismatched unrelated (57%) donors using FE2B2 conditioning and post-transplant cyclophosphamide-based GVHD prophylaxis.
Primary endpoint was 2- and 5-year overall survival, with secondary endpoints evaluating engraftment, GVHD incidence, non-relapse mortality, and progression-free survival across a median follow-up of 61 months.
Neutrophil engraftment occurred in 100% of recipients and platelet engraftment in 97%, with cumulative grade II–IV acute GVHD of 45% (95% CI, 34–59%) and chronic GVHD of 20% (95% CI, 13–32%) at 2 and 5 years.
Non-relapse mortality was 22% (95% CI, 14–34%) at 2 years and 25% (95% CI, 17–39%) at 5 years, with four early fatal toxicities reported within the first 20 days.
Two- and 5-year overall survival rates were 48% (95% CI, 35–60%) and 37% (95% CI, 25–49%), while progression-free survival was 43% (95% CI, 31–55%) and 32% (95% CI, 21–44%), respectively.

Cite This Study

Volpari et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6635f706d05830e4d45 https://doi.org/10.1007/s00277-026-07260-1

View Full Paper

Ask AI

Bookmark